Companies VBI Vaccines Inc/BC
VBI Vaccines Inc/BC CEO salary & total pay, FY2023: $894K
VBI Vaccines Inc/BC (VBIVQ) CEO salary, fiscal 2023: Jeffrey Baxter was paid a salary of $697,928 and $893,546 in total compensation. Free brief. Every figure links to the company’s own filing.
VBI Vaccines Inc/BC no longer files a proxy statement; its last pay data is FY2023.
Jeffrey Baxter's complete compensation dossier
A PDF and a CSV sent to your email: Jeffrey Baxter's pay in every fiscal year VBI Vaccines Inc/BC reported it, line by line, with Jeffrey Baxter's equity grants and VBI Vaccines Inc/BC's disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $1,830,436FY2022
- $893,546FY2023
CEO total pay was $893,546 in fiscal 2023, down from $1,830,436 in fiscal 2022.
FY2023: salary $697,928 · bonus $0 · stock awards $0 · option awards $121,736
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Baxter | $697,928 | $0 | $0 | $121,736 | $0 | $0 | $73,883 | $893,546 |
| President, Chief Executive Officer | ||||||||
| David Anderson | 458,350 | 0 | 0 | 91,305 | 0 | 0 | 14,900 | 564,555 |
| Chief Scientific Officer | ||||||||
| Francisco Diaz-Mitoma | 457,916 | 0 | 0 | 91,305 | 0 | 0 | 0 | 549,221 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Jeffrey Baxter | $893,546 | $1,830,436 | — | ↓ −936,890 |
| David Anderson | 564,555 | 995,438 | — | ↓ −430,883 |
| Francisco Diaz-Mitoma | 549,221 | 1,005,705 | — | ↓ −456,484 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
VBI's compensation program aims to attract, motivate, and retain skilled individuals by aligning executive interests with stakeholders through a mix of base salary, annual cash bonuses, spot recognition awards, and equity grants that reward short-term and long-term performance.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| David Anderson | Option | 16,146 | 520 | 94.5 | — |
| David Anderson | Option | 7,922 | 5,411 | 45.9 | — |
| David Anderson | Option | — | 2,500 | 17.25 | — |
| David Anderson | Option | — | 52,500 | 1.3 | — |
| David Anderson | Option | 5,760 | — | 123.9 | — |
| David Anderson | Option | 3,901 | — | 147.9 | — |
| David Anderson | Option | 666 | — | 113.7 | — |
| David Anderson | Option | 3,333 | — | 125.7 | — |
| David Anderson | Option | 10,000 | — | 50.1 | — |
| David Anderson | Option | 11,666 | — | 43.8 | — |
| David Anderson | Option | 5,670 | — | 88.2 | — |
| Francisco Diaz-Mitoma | Option | 16,146 | 520 | 94.2 | — |
| Francisco Diaz-Mitoma | Option | 7,922 | 5,411 | 45.9 | — |
| Francisco Diaz-Mitoma | Option | — | 2,500 | 17.25 | — |
| Francisco Diaz-Mitoma | Option | — | 52,500 | 1.3 | — |
| Francisco Diaz-Mitoma | Option | 666 | — | 108.3 | — |
| Francisco Diaz-Mitoma | Option | 3,333 | — | 116.7 | — |
| Francisco Diaz-Mitoma | Option | 10,000 | — | 49.2 | — |
| Francisco Diaz-Mitoma | Option | 11,666 | — | 49.8 | — |
| Francisco Diaz-Mitoma | Option | 5,571 | — | 89.7 | — |
| Jeffrey Baxter | Option | 32,291 | 1,041 | 94.5 | — |
| Jeffrey Baxter | Option | 15,837 | 10,829 | 45.9 | — |
| Jeffrey Baxter | Option | — | 3,333 | 17.25 | — |
| Jeffrey Baxter | Option | — | 70,000 | 1.3 | — |
| Jeffrey Baxter | Option | 13,069 | — | 123.9 | — |
| Jeffrey Baxter | Option | 5,202 | — | 147.9 | — |
| Jeffrey Baxter | Option | 666 | — | 113.7 | — |
| Jeffrey Baxter | Option | 5,000 | — | 125.7 | — |
| Jeffrey Baxter | Option | 15,000 | — | 50.1 | — |
| Jeffrey Baxter | Option | 16,666 | — | 43.8 | — |
| Jeffrey Baxter | Option | 14,173 | — | 88.2 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Steven GillisIndependent · Board Chair · Audit Committee · Compensation Committee · Nominating and Governance Committee (Chair) | $103,750 | — | $90,280 | — | $0 | $194,028 |
| Joanne CordeiroIndependent · Audit Committee · Compensation Committee (Chair) | 67,500 | — | 60,176 | — | 0 | 127,676 |
| Blaine H. McKeeIndependent · Audit Committee (Chair) | 60,000 | — | 60,176 | — | 0 | 120,176 |
| Michel De WildeIndependent · Compensation Committee | 47,500 | — | 60,176 | — | 0 | 107,676 |
| Damian BragaIndependent · Nominating and Governance Committee | 45,000 | — | 60,176 | — | 0 | 105,176 |
| Vaughn HimesIndependent · Nominating and Governance Committee | 33,750 | — | 54,401 | — | 0 | 88,151 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $357,500 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $357,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names VBI Vaccines Inc/BC as a peer
Companies that benchmark against VBIVQ
No companies currently name VBIVQ as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Disclosed peer group — fiscal year 2023
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Peer reciprocity
The companies VBI Vaccines Inc/BC names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Novavax, Inc. | 2025 | John Jacobs | $792,917 | $3,545,435 | $3,763,292 | $640,331 | $8,856,015 |
| 2 | Dynavax Technologies Corporation | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 3 | Akebia Therapeutics, Inc. | 2025 | John Butler | 864,010 | 2,164,338 | 2,024,798 | 580,973 | 5,652,339 |
| 4 | Emergent BioSolutions Inc. | 2025 | Joseph Papa | 1,037,385 | 1,638,500 | 1,191,500 | 1,446,640 | 5,321,147 |
| 5 | Rigel Pharmaceuticals, Inc. | 2025 | Raul Rodriguez | 787,405 | 951,327 | 2,241,570 | 634,649 | 4,658,805 |
| 6 | Heron Therapeutics, Inc. | 2025 | Craig Collard | 689,431 | 946,254 | 1,352,917 | 517,189 | 3,516,291 |
| 7 | Gritstone bio, Inc. | 2023 | Andrew Allen | 645,833 | 2,429,830 | 0 | 355,208 | 3,444,071 |
| 8 | C4 Therapeutics, Inc. | 2025 | Andrew Hirsch | 694,925 | 710,730 | 848,007 | 573,313 | 2,940,975 |
| 9 | Assembly Biosciences, Inc. | 2025 | Jason Okazaki | 647,500 | 661,671 | 573,574 | 585,000 | 2,482,987 |
| 10 | Sangamo Therapeutics, Inc. | 2024 | Alexander Macrae | 716,366 | 909,400 | 0 | 825,254 | 2,457,450 |
| 11 | Precision BioSciences, Inc. | 2025 | Michael Amoroso | 650,875 | 1,025,086 | 0 | 0 | 2,189,467 |
| 12 | Inovio Pharmaceuticals, Inc. | 2025 | Jacqueline Shea | 728,000 | 346,101 | 351,955 | 144,144 | 1,587,155 |
| 13 | Homology Medicines, Inc. | 2025 | Jodie Morrison | 645,600 | 335,280 | 220,792 | 355,080 | 1,558,870 |
| 14 | Chimerix, Inc. | 2023 | Mike Sherman | 514,695 | 183,112 | 778,511 | 0 | 1,517,854 |
| 15 | Agenus Inc. | 2025 | Garo Armen | 715,260 | 0 | 141,000 | 0 | 1,350,325 |
| 16 | VBI Vaccines Inc/BC | 2023 | Jeffrey Baxter | 697,928 | 0 | 121,736 | 0 | 893,546 |
| — | Adaptimmune Therapeutics plc. | — | — | — | — | — | — | not in coverage universe |
| — | Jounce Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Karyopharm Therapeutics Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Vaxart Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Vaxxinity, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Icosavax, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Axcella Health Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| VBI Vaccines Inc/BC | not disclosed | Option 100 | not disclosed | not disclosed |
| Adaptimmune Therapeutics plc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Agenus Inc. | 125% | Options 100 | not disclosed | Aon Radford |
| Akebia Therapeutics, Inc. | 90% | Options 50 · RSU 25 · MSU 25 | No | Pearl Meyer |
| Assembly Biosciences, Inc. | not disclosed | not disclosed | No | Alpine Rewards, LLC |
| Axcella Health Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| C4 Therapeutics, Inc. | 120% | not disclosed | not disclosed | Pearl Meyer |
| Chimerix, Inc. | 85% | Option 86 · RSU 14 | not disclosed | Aon |
| Dynavax Technologies Corporation | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Emergent BioSolutions Inc. | 107% | Options 50 · PSU 50 | No | WTW |
| Gritstone bio, Inc. | 100% | RSU 100 | not disclosed | Aon |
| Heron Therapeutics, Inc. | 100% | Option 66.67 · RSU 33.33 | not disclosed | Compensia, Inc. |
| Homology Medicines, Inc. | not disclosed | not disclosed | not disclosed | Aon plc |
| Icosavax, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Inovio Pharmaceuticals, Inc. | 33% | not disclosed | Yes — Relative TSR | Aon (Human Capital Solutions practice) |
| Jounce Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Karyopharm Therapeutics Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Novavax, Inc. | 95% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Precision BioSciences, Inc. | 115% | RSU 100 | not disclosed | Aon |
| Rigel Pharmaceuticals, Inc. | 124% | Options 75 · RSU 25 | No | Pearl Meyer |
| Sangamo Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Vaxart Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Vaxxinity, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-06-25 | — | — | — | — | — |
| 2023 | 2023-06-23 | 2,262,957 | 230,128 | 40,773 | 90.77% | Passed |
| 2022 | 2022-06-22 | — | — | — | — | — |
| 2021 | 2021-06-09 | — | — | — | — | — |
| 2020 | 2020-06-18 | 123,630,419 | 0 | 2,185,126 | 100% | Passed |
| 2019 | 2019-06-13 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-06-25 | —a |
| 2023 | 2023-06-23 | 90.77%b |
| 2022 | 2022-06-22 | —c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “The affirmative vote of the holders of Common Shares having a majority of the votes cast by the holders of all Common Shares present or represented and voting on such matter will be required for approval, on an advisory basis, of the compensation of our Named Executive Officers (the "Named Executive Officers" or "NEOs") as set forth in the accompanying Proxy Statement.”.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (31 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Jeffrey Baxter. DEF 14A, filed 2024-04-29. Section “Summary Compensation Table for 2023 and 2022” · page 38. As printed: 893,546. View filing ↗
- Section 01, David Anderson. DEF 14A, filed 2024-04-29. Section “Summary Compensation Table for 2023 and 2022” · page 38. As printed: 564,555. View filing ↗
- Section 01, Francisco Diaz-Mitoma. DEF 14A, filed 2024-04-29. Section “Summary Compensation Table for 2023 and 2022” · page 38. As printed: 549,221. View filing ↗
- Section 08, Steven Gillis. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 194,028. View filing ↗
- Section 08, Joanne Cordeiro. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 127,676. View filing ↗
- Section 08, Blaine H. McKee. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 120,176. View filing ↗
- Section 08, Michel De Wilde. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 107,676. View filing ↗
- Section 08, Damian Braga. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 105,176. View filing ↗
- Section 08, Vaughn Himes. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 88,151. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-25. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-23. Item 5.07 · say-on-pay result. As reported: 90.77% (votes for as printed: 2,262,957). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-06-23. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 357,500 + equity 0 + all other 0 = 357,500, summed across the director compensation table rows.
- Novavax, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Novavax, Inc.'s own proxy. As printed: 8,856,015. View filing ↗
- Dynavax Technologies Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Dynavax Technologies Corporation's own proxy. As printed: 8,210,775. View filing ↗
- Akebia Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Akebia Therapeutics, Inc.'s own proxy. As printed: 5,652,339. View filing ↗
- Emergent BioSolutions Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Emergent BioSolutions Inc.'s own proxy. As printed: 5,321,147. View filing ↗
- Rigel Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Rigel Pharmaceuticals, Inc.'s own proxy. As printed: 4,658,805. View filing ↗
- Heron Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Heron Therapeutics, Inc.'s own proxy. As printed: 3,516,291. View filing ↗
- Gritstone bio, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Gritstone bio, Inc.'s own proxy. As printed: 3,444,071. View filing ↗
- C4 Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in C4 Therapeutics, Inc.'s own proxy. As printed: 2,940,975. View filing ↗
- Assembly Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Assembly Biosciences, Inc.'s own proxy. As printed: 2,482,987. View filing ↗
- Sangamo Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-30. CEO total compensation as printed in Sangamo Therapeutics, Inc.'s own proxy. As printed: 2,457,450. View filing ↗
- Precision BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Precision BioSciences, Inc.'s own proxy. As printed: 2,189,467. View filing ↗
- Inovio Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Inovio Pharmaceuticals, Inc.'s own proxy. As printed: 1,587,155. View filing ↗
- Homology Medicines, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Homology Medicines, Inc.'s own proxy. As printed: 1,558,870. View filing ↗
- Chimerix, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in Chimerix, Inc.'s own proxy. As printed: 1,517,854. View filing ↗
- Agenus Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Agenus Inc.'s own proxy. As printed: 1,350,325. View filing ↗
- VBI Vaccines Inc/BC (subject), Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in VBI Vaccines Inc/BC's own proxy. As printed: 893,546. View filing ↗
- Section 10a, Chimerix, Inc. reciprocity. DEF 14A. Chimerix, Inc. names VBI Vaccines Inc/BC in its own disclosed peer group (read from its most recent proxy). View filing ↗